Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
182 Results for "
hematologic malignancy
" in MedChemExpress (MCE) Product Catalog:
Products (182)
182 Results for "hematologic malignancy" in MCE Product Catalog:
Cat. No.: HY-180561
CAS No.: 3076807-15-0
Target:
Research Areas:
WWQ-03-012 is a selective DESI2 inhibitor with an IC50 of 47.3 nM. WWQ-03-012 binds covalently to DESI2, blocks its enzymatic activity, and inhibits DESI2-mediated deSUMOylation, deubiquitination and stabilization of mutant JAK2, thereby promoting the complete degradation of mutant JAK2 via the intracellular ubiquitin-proteasome system and inducing apoptosis, while exerting no significant effect on wild-type JAK2. WWQ-03-012 can be used for research on myeloproliferative neoplasms (MPN) and secondary acute myeloid leukemia (sAML), especially for hematological malignancies carrying the JAK2-V617F mutation and those resistant to Ruxolitinib (HY-50856) .
Cat. No.: HY-W018324
CAS No.: 1123-95-1
Synonyms: 5hmC
Target:
Cat. No.: HY-183817
CAS No.: 2484742-13-2
Research Areas:
GNE-781-COOH is a CBP/p300 degrader. GNE-781-COOH also acts as a ligand for target protein for PROTAC (Ligands for Target Protein for PROTAC), which can be used to synthesize PROTAC CBP/P300 Degrader-4 (HY-183802) .
Cat. No.: HY-187360
CAS No.: 3087291-81-1
Target:
Research Areas:
MC-Val-Ala-PAB-NH-Ph-CO-piperidin-4-ol-C4-NH-cyanoguanidine is a cathepsin B-cleavable linker-payload, with Nampt-IN-22 (HY-187336) as its toxin moiety. MC-Val-Ala-PAB-NH-Ph-CO-piperidin-4-ol-C4-NH-cyanoguanidine can be used for the synthesis of ADC .
Cat. No.: HY-A0003R
CAS No.: 191732-72-6
Synonyms: CC-5013 (Standard)
Lenalidomide (Standard) (CC-5013 (Standard)) is the analytical standard of Lenalidomide (HY-A0003). This product is intended for research and analytical applications. Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8 + T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury .
Cat. No.: HY-P990033
CAS No.: 2543693-10-1
Synonyms: CC-95251; BMS-986351
Cat. No.: HY-A0003S
CAS No.: 1227162-34-6
Synonyms: CC-5013-d5
Lenalidomide-d5 (CC-5013-d5) is the d5-labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8 + T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury .
Cat. No.: HY-A0003S2
Synonyms: CC-5013-13C5,15N
Lenalidomide- 13C5, 15N (CC-5013- 13C5, 15N) is the 13C, 15N-labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8 + T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury .
Cat. No.: HY-A0003S3
CAS No.: 1130061-52-7
Synonyms: CC-5013-d4
Lenalidomide-d4 (CC-5013-d4) is the d4-labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8 + T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury .
Cat. No.: HY-W777286
CAS No.: 1219332-91-8
Synonyms: CC-5013-13C5
rac-Lenalidomide- 13C5 (CC-5013- 13C5) is the 13C5-labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013) is an orally active immunomodulatory agent that binds CRBN as a molecular glue to alter substrate specificity, inducing ubiquitination and proteasome-dependent degradation of IKZF1, IKZF3 and CK1α. Lenalidomide induces apoptosis by degrading IKZF1/3, and activates p53 by degrading CK1α. Lenalidomide promotes IL-2 release and effector functions of CD8 + T/NK cells, while inhibiting TNF-α secretion and M1-type pyroptosis. Lenalidomide can be used in research related to hematological malignancies, acute liver failure and acute kidney injury .
Cat. No.: HY-13650R
CAS No.: 165668-41-7
Synonyms: E 7070 (Standard)
Research Areas:
Indisulam (Standard) (E 7070 (Standard)) is the analytical standard of Indisulam (HY-13650). This product is intended for research and analytical applications. Indisulam (E 7070) is a carbonic anhydrase inhibitor and RBM39 molecular glue degrader, with Ki values of 31, 15, and 24 nM against human carbonic anhydrase I, II, and IX, respectively, and a Ki value of 65 nM against bovine carbonic anhydrase IV. Indisulam promotes the recruitment of RBM39 to the CUL4-DCAF15 E3 ubiquitin ligase complex, triggering polyubiquitination and proteasomal degradation of RBM39. Indisulam induces aberrant pre-mRNA splicing, G1 cell cycle arrest, and cell death in cancer cells. As an anticancer agent, Indisulam drives tumor regression and growth inhibition in xenograft models. Indisulam can be used in research related to solid tumors, hematologic and lymphoid malignancies, colorectal cancer, and non-small cell lung cancer .
PI3Kδ-IN-16 is a potent and selective PI3Kδ inhibitor with an IC50 value of 0.9 nM. PI3Kδ-IN-16 has a strong anti-proliferative effect on SU-DHL-6 cells, causing cell cycle arrest and inducing apoptosis. PI3Kδ-IN-16 tightly bins to PI3Kδ protein with a planar-shaped conformation. The kinase activity of PI3Kδ-IN-16 which is ~378-fold over PI3Kα, 412-fold over PI3Kβ, and 10-fold over PI3Kγ. PI3Kδ-IN-16 can be used for the study of hematologic malignancies .
Cat. No.: HY-P990954
CAS No.: 2850355-94-9
Synonyms: IMM-0306
Amulirafusp alfa (IMM-0306) is a fusion protein of CD20 monoclonal antibody (mAb) with the CD47 binding domain of SIRPα, with human CD20 Kd 2.45 nM and human CD47 Kd 4.91 nM. Amulirafusp alfa binds to CD20 and CD47 on B cells, engages FcɣR, blocks CD47-SIRPα interaction, activates macrophages, NK cells, and complement cascade, mediates phagocytosis and cytotoxicity, inhibits apoptosis of Jurkat-CSR cells, reverses IL-16 tumor-promoting effects, and binds human/cynomolgus CD47 but not mouse/rat CD47. Amulirafusp alfa can be used for the research of hematological malignancies, relapsed or refractory CD20-positive B-cell non-Hodgkin’s lymphoma, relapsed or refractory B-cell non-Hodgkin lymphoma, and activated B-cell-like diffuse large B-cell lymphoma .
Cat. No.: HY-W018324S
Synonyms: 5hmC-13C,d2
Cat. No.: HY-183354
Research Areas:
HLC40 is a MLL1 histone methyltransferase inhibitor with an IC50 of 0.82 μM by binding to WDR5. HLC40 inhibits proliferation of cancer cells, induces apoptosis and upregulates cleaved caspase-3 levels. HLC40 exhibits antitumor efficacy in a murine AML xenograft model .
Cat. No.: HY-10446A
CAS No.: 1320211-69-5
Target:
Research Areas:
(S)-Pralatrexate is an orally active anticancer compound. (S)-Pralatrexate exhibits cytotoxic activity against cancer cells and possesses anti-inflammatory activity. (S)-Pralatrexate can be used in research related to prostate cancer, breast cancer, rheumatoid arthritis, etc.
Cat. No.: HY-184823
CAS No.: 1417634-25-3
Target:
Research Areas:
CK2-IN-17 is a protein kinase CK2 inhibitor with an IC50 of 9.5 μM against human targets. CK2-IN-17 regulates the activity of protein kinase CK2 by interacting with its ATP-binding site. CK2-IN-17 can be used in studies related to protein kinase CK2-mediated pathways, such as tumors .
Cat. No.: HY-P990905
CAS No.: 2871775-98-1
Synonyms: SAR-443579
Target:
Research Areas:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
